2-异丙基-3,5-二甲基吡啶 | 199617-23-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-异丙基-3,5-二甲基吡啶
• 英文名称: 3,5-dimethyl-2-iso-propylpyridine
• 英文别名: 3,5-Dimethyl-2-propan-2-ylpyridine
• CAS: 199617-23-7
• 化学式: C₁₀H₁₅N
• 分子量: 149.236
• InChiKey: MRMKRBSMWYEERT-UHFFFAOYSA-N

物化性质

• 沸点：
  211.4±9.0 °C(Predicted)
• 密度：
  0.902±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  1-benzyl-3,5-dimethyl-2-iso-propyl-1,2-dihydropyridine 在 palladium on activated charcoal air 、 氢气 作用下， 以 甲苯 为溶剂， 反应 24.0h， 以62 mg的产率得到2-异丙基-3,5-二甲基吡啶
  参考文献：
  名称：

  Synthesis of Dihydropyridines and Pyridines from Imines and Alkynes via C−H Activation

  摘要：

  A convenient one-pot C-H alkenylation/electrocyclization/aromatization sequence has been developed for the synthesis of highly substituted pyridine derivatives from alkynes and alpha,beta-unsaturated N-benzyl aldimines and ketimines that proceeds through dihydropyridine intermediates. A new class of ligands for C-H activation was developed, providing broader scope for the alkenylation step than could be achieved with previously reported ligands. Substantial information was obtained about the mechanism of the reaction. This included the isolation of a C-H activated complex and its structure determination by X-ray analysis; in addition, kinetic simulations using the Copasi software were employed to determine rate constants for this transformation, implicating facile C-H oxidative addition and slow reductive elimination steps.

  DOI：

  10.1021/ja7104784

文献信息

• COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF
  申请人：BioTheryX, Inc.

  公开号：US20180170948A1

  公开（公告）日：2018-06-21

  The present invention provides compounds that modulate protein function, to restore protein homeostasis, including cytokine, CK1α, GSPT1, aiolos, and/or ikaros activity, and cell-cell adhesion. The invention provides methods of modulating protein-mediated diseases, such as cytokine-mediated diseases, disorders, conditions, or responses. Compositions, including in combination with other cytokine and inflammatory mediators, are provided. Methods of treatment, amelioration, or prevention of diseases, disorders, or conditions associated with a protein, such as diseases, disorders, and conditions associated with cytokines, including inflammation, fibromyalgia, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, inflammatory bowel diseases, Crohn's disease, ulcerative colitis, uveitis, inflammatory lung diseases, chronic obstructive pulmonary disease, Alzheimer's disease, and cancer, are provided.

  本发明提供了调节蛋白功能的化合物，以恢复蛋白稳态，包括细胞因子、CK1α、GSPT1、艾奥洛斯和/或伊卡洛斯活性和细胞间粘附。该发明提供了一种调节蛋白介导的疾病的方法，如细胞因子介导的疾病、障碍、状况或反应。提供了包括与其他细胞因子和炎症介质结合的组合物。提供了治疗、改善或预防与蛋白相关的疾病、障碍或状况的方法，包括与细胞因子相关的疾病、障碍和状况，包括炎症、纤维肌痛、类风湿性关节炎、骨关节炎、强直性脊柱炎、银屑病、银屑病关节炎、炎症性肠病、克罗恩病、溃疡性结肠炎、葡萄膜炎、炎症性肺病、慢性阻塞性肺病、阿尔茨海默病和癌症。
• AMINOTHIAZINE OR AMINOOXAZINE DERIVATIVE HAVING AMINO LINKER
  申请人：Masui Moriyasu

  公开号：US20120238557A1

  公开（公告）日：2012-09-20

  The present invention provide a medicament for treating the diseases induced by production, secretion or deposition of amyloid-β proteins, for example, a compound of the following formula (I) wherein R 1 , R 2a , R 2b , R 3 , R 4 , R 5 , X, L 1 , L 2 , A, ring B and the dotted line are defined in the specification, its pharmaceutically acceptable salt or a solvate thereof.

  本发明提供了一种治疗由淀粉样蛋白β的产生、分泌或沉积引起的疾病的药物，例如以下式(I)的化合物，其中R1、R2a、R2b、R3、R4、R5、X、L1、L2、A、环B和虚线在规范中有定义，其药学上可接受的盐或溶剂化合物。
• FUSED HETEROCYCLIC COMPOUND HAVING AMINO GROUP
  申请人：Yoshida Syuhei

  公开号：US20120245155A1

  公开（公告）日：2012-09-27

  The present invention provides, for example, a compound mentioned below as a medicament for treating or preventing the diseases induced by production, secretion or deposition of amyloid-βproteins. A compound of the formula (I): wherein R 1 , R 2a , R 2b , R 3 , R 4 , R 5a , R 5b , R 6a , R 6b , X, Y, Z, ring A and the dashed lines are defined in the specification, its pharmaceutically acceptable salt or a solvate thereof.

  本发明提供了一个如下所述的化合物作为治疗或预防由淀粉样β蛋白的产生、分泌或沉积引起的疾病的药物。式（I）的化合物：其中R1、R2a、R2b、R3、R4、R5a、R5b、R6a、R6b、X、Y、Z、环A和虚线在说明书中定义，其药用可接受的盐或其溶剂化合物。
• [EN] OGA INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS D'OGA
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2018141984A1

  公开（公告）日：2018-08-09

  The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors of Formulas (I) and (II). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C90RF72 mutations.

  本发明涉及具有式(I)和(II)的O-GlcNAc水解酶（OGA）抑制剂。该发明还涉及包含这些化合物的药物组合物，用于制备这些化合物和组合物的过程，以及利用这些化合物和组合物预防和治疗OGA抑制对其有益的疾病的用途，如tau病变，特别是阿尔茨海默病或进行性上行性麻痹; 伴有tau病理的神经退行性疾病，特别是由C90RF72突变引起的肌萎缩性侧索硬化或额颞叶痴呆。
• OXAZINE DERIVATIVES AND A PHARMACEUTICAL COMPOSITION FOR INHIBITING BACE1 CONTAINING THEM
  申请人：Masui Moriyasu

  公开号：US20140051691A1

  公开（公告）日：2014-02-20

  The present invention provides a compound of formula (I): wherein —X═ is —CR 7 ═ or —N═, ring B is a substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle, R 1 is substituted or unsubstituted alkyl or the like, R 2 a and R 2 b are each independently hydrogen, substituted or unsubstituted alkyl or the like, R 3 and R 4 are each independently hydrogen, halogen, substituted or unsubstituted alkyl or the like, R 5 is hydrogen, substituted or unsubstituted alkyl or the like, each R 6 is independently halogen, hydroxy, substituted or unsubstituted alkyl or the like, R 7 is hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl or the like, p is an integer of 0 to 3, or a pharmaceutically acceptable salt thereof which has an effect of inhibiting amyloid β production, especially an effect of inhibiting BACE1, and which is useful as a therapeutic or prophylactic agent for diseases induced by production, secretion and/or deposition of amyloid β proteins.

  本发明提供了一种化合物的公式(I)：其中—X═是—CR7═或—N═，环B是取代或未取代的碳环或取代或未取代的杂环，R1是取代或未取代的烷基或类似物，R2和R2'分别独立地是氢、取代或未取代的烷基或类似物，R3和R4分别独立地是氢、卤素、取代或未取代的烷基或类似物，R5是氢、取代或未取代的烷基或类似物，每个R6独立地是卤素、羟基、取代或未取代的烷基或类似物，R7是氢、卤素、羟基、取代或未取代的烷基或类似物，p是0到3的整数，或其在药学上可接受的盐，具有抑制淀粉样蛋白β产生的作用，特别是抑制BACE1的作用，并且可用作由淀粉样蛋白β蛋白的产生、分泌和/或沉积引起的疾病的治疗或预防剂。